Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Adenocarcinoma × darolutamide × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 7 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Prostate Cancer Non-Metastatic 1 Prostate Cancer Metastatic 1 Prostate Adenocarcinoma 1 Neoplasms 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Genital Diseases, Male 1 Biochemically Recurrent Prostate Cancer 1 Adenocarcinoma 1

Interventions

Oxaliplatin 8 Fluorouracil 6 Docetaxel 6 Paclitaxel 5 Leucovorin 5 Gemcitabine 5 Capecitabine 5 zolbetuximab 4 Cisplatin 4 Ramucirumab 3 Pemetrexed 3 Drug Therapy 3 Carboplatin 3 Albumin-Bound Paclitaxel 3 130-nm albumin-bound paclitaxel 3 regorafenib 2 pembrolizumab 2 Vinorelbine 2 Surgical Procedures, Operative 2 Nivolumab 2 Neoadjuvant Therapy 2 Cyclophosphamide 2 Chemoradiotherapy 2 Bevacizumab 2 Afatinib 2 vandetanib 1 trifluridine tipiracil drug combination 1 trastuzumab deruxtecan 1 tislelizumab 1 pralsetinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06592924 2026-01-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡